Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recruitment failure
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to evaluate whether sitagliptin can affect postprandial lipoprotein metabolism in type 2 diabetic patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| sitagliptin | Experimental |
| |
| glimepirid | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sitagliptin | Drug | sitagliptin 100 mg/d for 10 weeks |
| |
| glimepiride |
| Measure | Description | Time Frame |
|---|---|---|
| incremental area under the triglyceride curve (iAUC-TG) | incremental area under the plasma triglyceride concentration curve following a standardized oral fat challenge | 10 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| LDL-cholesterol | fasting LDL-cholesterol | 10 weeks |
| HDL-cholesterol | fasting HDL-cholesterol | 10 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Dept. 2, Grosshadern, University Munich | Munich | 81377 | Germany |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068900 | Sitagliptin Phosphate |
| C057619 | glimepiride |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
glimepiride 1 mg/d for 10 weeks |
|
| VLDL-cholesterol | fasting VLDL-cholesterol | 10 weeks |
| triglycerides | fasting triglycerides | 10 weeks |
| area under the triglyceride curve (AUC-TG) | area under the plasma triglyceride concentration curve following a standardized oral fat challenge | 10 weeks |
| area under the VLDL-triglyceride curve (AUC-VLDL-TG) | area under the plasma VLDL-triglyceride concentration curve following a standardized oral fat challenge | 10 weeks |
| incremental area under the VLDL-triglyceride curve (iAUC-VLDL-TG) | incremental area under the plasma VLDL-triglyceride concentration curve following a standardized oral fat challenge | 10 weeks |
| glucose | fasting glucose concentration | 10 weeks |
| insulin | fasting insulin concentration | 10 weeks |
| HOMA | 10 weeks |
| HbA1c | 10 weeks |
| interleukin-6 | 10 weeks |
| hs-CRP | 10 weeks |
| D004700 | Endocrine System Diseases |
| D011719 |
| Pyrazines |